Skip to main content

Priapism

Priapism is a persistent penile erection lasting more than 4 hours in the absence of sexual stimulation and not relieved by ejaculation or orgasm.[1][2] It is classified by pathophysiology into three subtypes — ischemic (low-flow, veno-occlusive), non-ischemic (high-flow, arterial), and stuttering (recurrent ischemic) — each with fundamentally different management pathways. Ischemic priapism accounts for roughly 95% of cases and is a urologic emergency: beyond 4 hours, progressive ischemia, acidosis, smooth-muscle injury, and fibrosis destroy corporal tissue, and beyond 24 hours the window for medical detumescence closes and surgical intervention becomes near-mandatory.[3][4]

Management is governed by the 2021 AUA/SMSNA Guideline on Acute Ischemic Priapism and the 2022 AUA/SMSNA Guideline on Recurrent Ischemic, Sickle-Cell, and Non-Ischemic Priapism.[2][3]

Classification and Pathophysiology​

Ischemic (low-flow, veno-occlusive) priapism​

Venous outflow obstruction → blood stasis in the corpora cavernosa → progressive hypoxia, hypercapnia, acidosis, and eventually smooth-muscle necrosis and fibrosis. The corpora are rigid and painful; the glans is soft (spongiosum is not involved).[1]

Corporal blood gas:

ParameterIschemicNormal arterial
pO₂<30 mmHg>90 mmHg
pCO₂>60 mmHg<40 mmHg
pH<7.25~7.40
ColorDark, deoxygenatedBright red

Non-ischemic (high-flow, arterial) priapism​

Uncontrolled arterial inflow via an arteriocavernosal fistula, usually after blunt perineal or penile trauma (straddle injury, saddle trauma). The corpora remain oxygenated; the erection is partial and non-painful. This is not a surgical emergency — observation is first-line.[1][4]

Stuttering (recurrent ischemic) priapism​

Repeated self-limited ischemic episodes, typically <3 hours each, with intervening detumescence. Pathophysiologically ischemic and a risk factor for prolonged ischemic events.[3][5]

Molecular mechanisms (ischemic)​

  • Dysregulation of the NO–cGMP–PDE5 pathway — chronic hypoxia reduces endothelial NO and alters PDE5 set-point
  • Rho-Rho kinase pathway dysregulation
  • Adenosine accumulation — signals through A2B receptor to drive fibrosis[6]
  • Oxidative stress and reactive-oxygen-species injury
  • In sickle-cell disease: intravascular hemolysis → impaired NO bioavailability → exaggerated corpus cavernosum relaxation and sickling in the corpora during nocturnal tumescence[7][8]

Epidemiology and Etiology​

CauseComment
Sickle cell diseaseMost common identifiable cause; ~40% lifetime prevalence in men with SCD; actuarial probability of priapism by age 20 approaches 89% in homozygous SCD[5][9]
Intracavernosal injection therapyMajor cause — papaverine, phentolamine, PGE1 (alprostadil); can account for >50% of cases in some series[10]
MedicationsAntipsychotics (trazodone, chlorpromazine, risperidone), α-blockers, anticoagulants, recreational cocaine
Hematologic disordersThalassemia, polycythemia vera, multiple myeloma, CML/CLL
MalignancyMetastatic infiltration of corpora (rare but reported — bladder, prostate, renal primaries)
NeurologicSpinal cord injury (especially cervical), autonomic dysreflexia
IdiopathicSignificant proportion of adult cases
TraumaPerineal/straddle injury — non-ischemic (high-flow) priapism specifically

Initial Evaluation​

History​

  • Duration of erection (drives the urgency of intervention)
  • Preceding sexual activity, perineal trauma, recreational drugs, new medications
  • Prior priapism episodes (stuttering pattern)
  • Known sickle-cell, thalassemia, leukemia
  • Current ICI use and agent

Physical examination​

  • Ischemic: rigid corpora, soft glans, painful
  • Non-ischemic: partially tumescent, non-painful, may have perineal ecchymosis
  • Examine perineum and genitalia for evidence of recent trauma

Corporal blood gas​

The gold-standard diagnostic. A 19–21 gauge needle is placed laterally into the corpus cavernosum (avoiding the dorsal neurovascular bundle at 12 o'clock and the urethra at 6 o'clock). Aspirate; color is the first clue. Send for gas analysis. Do this before any pharmacologic intervention — it is both diagnostic and therapeutic (see aspiration below).[1][4]

Imaging​

  • Color Doppler ultrasound (CDUS) — used when blood gas is equivocal or when non-ischemic is suspected. Ischemic: absent or minimal cavernosal arterial flow. Non-ischemic: high arterial flow, often with visible arteriocavernosal fistula.[11][12]
  • MRI — useful in delayed presentations (>36–48 hours) to assess extent of cavernosal necrosis and fibrosis; informs early-implant decision
  • CT/MR angiography — defines pudendal arterial anatomy for selective embolization in non-ischemic priapism

Management — Ischemic Priapism (the Acute Emergency)​

The AUA/SMSNA algorithm is stepwise and time-pressured — each step is attempted and, if unsuccessful, escalated quickly.[2]

Step 1 — Corporal aspiration​

Laterally into the corpus cavernosum; aspirate 20–30 mL of dark blood. Aspiration alone resolves a subset of early-presentation priapism and decompresses the corpora for subsequent pharmacologic therapy.

Step 2 — Intracavernosal phenylephrine​

Phenylephrine is the α-agonist of choice due to its pure α1 selectivity (minimizing β-mediated tachycardia and hypertensive crisis).[13]

  • Dilution: 1 mg phenylephrine in 10 mL saline → 100 mcg/mL
  • Dose: 100–500 mcg per injection (1–5 mL of the dilution)
  • Frequency: every 3–5 minutes up to 1 hour of attempted resolution
  • Monitoring: continuous BP and HR; meaningful risk of hypertensive crisis, particularly in children and patients with cardiovascular disease
  • Pediatric dosing: 100 mcg doses, maximum 500 mcg total; consider cardiology monitoring

Step 3 — Repeat aspiration and irrigation​

Corporal saline irrigation combined with re-aspiration can clear residual coagulum and facilitate re-inflation of the corpora with oxygenated blood.

Step 4 — Surgical shunting (if medical management fails within 4–24 hours)​

The shunt creates a communication between the rigid corpus cavernosum and either the glans or the corpus spongiosum, allowing stasis blood to drain.

For detailed operative technique comparisons, see Priapism Shunts & Decompression.

Distal shunts (attempted first):

ShuntTechnique
WinterPercutaneous large-bore biopsy needle (Tru-Cut) through the glans into the distal corpus cavernosum, creating a fistula
EbbehojStab incision with a scalpel through the glans into the distal corpus cavernosum
T-shuntT-shaped scalpel incision distally through the glans into corpus cavernosum (variant of Ebbehoj)
Al-GhorabOpen excision of a segment of distal tunica albuginea via circumcision or subcoronal incision — more durable than Winter/Ebbehoj

Proximal shunts (if distal fail):

Step 5 — Distal tunneling procedures (modern addition)​

Tunneling extends the distal shunt by passing a dilator (Hegar or Mecholl) proximally through the cavernosum from the shunt site to disrupt ischemic coagulum along the entire length of the corpus. Added to the 2021 AUA/SMSNA guideline based on improving outcomes:[2]

  • Burnett snake technique — Al-Ghorab shunt + retrograde corporal tunneling with a 7/8 Hegar dilator
  • Penoscrotal decompression (PSD) — glans-sparing proximal corporal decompression through penoscrotal or proximal shaft corporotomies; increasingly used as salvage after failed distal shunts and as an alternative primary surgical strategy for prolonged ischemic priapism[14][18][19][20]

Step 5b — Penoscrotal decompression (PSD)​

PSD treats prolonged ischemic priapism as a corporal compartment syndrome. Instead of creating a corporoglanular fistula through the glans, PSD opens the proximal corpora, evacuates stagnant blood and clot directly, irrigates the corporal bodies, and closes the corporotomies. This can spare the glans and avoid some distal-shunt complications while preserving the option for later elective penile prosthesis placement if erectile function does not recover.[18][19]

When to consider PSD:

ScenarioRole of PSD
Failed aspiration / irrigation / phenylephrineSurgical decompression option when medical detumescence fails
Failed distal shunt or failed corporoglanular tunnelingSalvage strategy that bypasses the glans and directly clears proximal corporal clot
Prolonged ischemic priapism, especially >36–48 hAlternative to glans-based shunting in centers familiar with the technique; counsel that erectile recovery remains time-dependent
PSD failure or very late presentation with nonviable corporaProceed to penile prosthesis rather than repeating ineffective decompression

Technique options:

ApproachExposureTechnical notes
Original penoscrotal approachLongitudinal or transverse incision at the penoscrotal junction; familiar to implant surgeonsExpose ventrolateral tunica, protect urethra with a Foley catheter, perform 2–3 cm longitudinal corporotomy, evacuate dark blood and clot, irrigate to clear return, repeat contralaterally, close tunica with absorbable suture[18][19]
Modified proximal shaft approachProximal penile shaft incision or degloving exposure, analogous to penile fracture repairMay make bilateral corporal exposure faster and more familiar for general urologists comfortable with fracture exploration; evacuation, irrigation, and tunical closure are otherwise the same[20]

Operative pearls:

  • Place a Foley catheter before dissection so the urethra / corpus spongiosum can be palpated and protected.
  • Put corporotomies on the ventrolateral corporal surface, away from the dorsal neurovascular bundle and away from the urethra.
  • Evacuate aggressively but deliberately: prolonged cases often contain viscous, gelatinous, or organized clot that will not drain through a small distal shunt.
  • Default to bilateral PSD. In the largest multi-institutional series, unilateral PSD had recurrence while bilateral PSD had none; the newer proximal-shaft series also favored bilateral decompression.[19][20]
  • Apply a light compressive dressing after closure; monitor for recurrent rigidity, hematoma, skin issues, and early pain relief.

Step 6 — Early penile prosthesis implantation​

For priapism >36–48 hours (or >48 hours per some guidelines), early prosthesis implantation is the modern standard when medical management fails.[15] Rationale:

  • After 36 hours of ischemia, the prognosis for preserved natural erectile function is essentially zero (only 43% retain any function after 48+ hours, and most of those have significant dysfunction)
  • Corporal fibrosis progresses rapidly after the acute phase — implantation is substantially easier in the acute period than after 4–6 weeks of fibrosis consolidation when cavernotomes become necessary and penile shortening is inevitable
  • Early implantation preserves penile length that is otherwise lost to progressive fibrosis
  • A malleable prosthesis is often placed acutely to manage detumescence; conversion to an inflatable can follow months later if desired

Counseling is critical: the decision is between a mechanical device now with better length, or a severely fibrosed corpora requiring a difficult revision-level implantation later with significant length loss.

See penile implants — revision scenarios for the cavernotome toolkit and Carter-Trost technique used in the fibrosed corpus.

Special Considerations — Sickle Cell Disease​

The 2022 AUA/SMSNA guideline is explicit:[3]

  • Do not delay urologic intervention for exchange transfusion. Exchange transfusion does not terminate priapism faster than standard urologic management and delays effective intervention by 6+ hours — an interval during which ischemic injury progresses.
  • Simple transfusion to Hb 9–10 g/dL is reasonable before general anesthesia if surgical shunting is needed, to reduce sickling risk intraoperatively.
  • ASPEN syndrome (association of sickle cell, priapism, exchange, and neurologic events) has been described after rapid exchange transfusion — another argument against reflexive exchange.

Chronic prevention in SCD​

After an acute episode resolves, prevention of recurrence is the main goal:

  • Hydroxyurea — standard-of-care SCD therapy reduces priapism episode frequency
  • Scheduled monthly transfusion programs in selected patients
  • Pseudoephedrine at bedtime (limited evidence)
  • PDE5 inhibitors — low-dose daily sildenafil has been used with the paradoxical rationale of restoring PDE5 regulatory tone; evidence is limited but mechanism is biologically plausible[5]
  • GnRH analogues / antiandrogens — effective but with significant side-effect profiles; reserved for refractory cases

Management — Non-Ischemic (High-Flow) Priapism​

Not an emergency. Management pathway:[1][3]

  1. Observation + conservative measures — ice packs, compression, avoidance of stimulation
  2. ~60% of high-flow priapism resolves spontaneously over weeks
  3. Selective arterial embolization — if the patient desires treatment or conservative measures fail
    • Autologous clot embolization (temporary, resorbable) — preferred first-line; high success rate (~90%) with preservation of erectile function
    • Non-absorbable agents (coils, gelfoam) — higher ED risk
  4. Surgical ligation — rarely needed; reserved for embolization failures

Management — Stuttering / Recurrent Ischemic Priapism​

Acute episode: treat exactly as acute ischemic priapism (aspiration + phenylephrine).

Preventive strategies (the 2022 AUA/SMSNA guideline frames these as "may offer" options given limited evidence):[3]

  • At-home phenylephrine self-injection — for episodes not yet meeting 4-hour threshold; patient must be thoroughly trained and aware of hypertensive-crisis risk
  • Daily low-dose PDE5 inhibitor (sildenafil 25–50 mg) — paradoxical but biologically plausible mechanism
  • α-agonist agents (pseudoephedrine, etilefrine where available)
  • Ketoconazole — antiandrogenic mechanism; occasionally tried
  • GnRH analogues / antiandrogens — effective but poorly tolerated
  • Hydroxyurea / chronic transfusion for SCD-associated stuttering

Outcomes​

Duration is the dominant predictor of ED​

DurationRisk of ED
<12 hoursLow
12–24 hoursModerate
24–36 hoursHigh
>36 hoursOR 61.3 for ED[10]
>48 hoursOnly ~43% retain any erectile function; most of those with significant dysfunction[16]

Other predictors​

  • Complete detumescence at the end of intervention is the strongest short-term predictor of recovery[16]
  • Degree of fibrosis on MRI — heterogeneous low-signal areas from hemosiderin and fibrosis correlate with ED severity
  • Medical management alone achieves complete detumescence in ~78% of acute ischemic priapism cases[17]
  • Surgical shunting is required in ~10% of cases overall; lower in SCD (2.2%) than non-SCD ischemic (15.2%) etiologies[17]

Long-term complications​

  • Erectile dysfunction — the dominant long-term morbidity
  • Penile fibrosis — progressive, adenosine-A2B-driven; detected in 57% of patients with prolonged priapism[6][16]
  • Penile shortening — especially with delayed prosthesis implantation
  • Acquired penile curvature
  • Psychological distress and relationship-impacting sexual dysfunction[5]

Prolonged Priapism (≥ 24 hours) — the Operative Window​

Prolonged ischemic priapism is a categorically different problem. After 24 hours, aspiration and phenylephrine rarely achieve detumescence, and the question becomes which surgical strategy rather than whether to operate.[4][14]

Distal shunts alone have limited durability in prolonged cases because the ischemic coagulum spans the entire corporal length. Success of traditional distal shunting falls as duration passes 36–48 hours, and glans-based shunts can be limited by recurrent occlusion, urethral injury, cavernosospongiosal fistula, and the inability to clear proximal clot.[14][18][23]

Where PSD fits​

PSD sits between distal tunneling and acute penile prosthesis. It is best framed as a glans-sparing proximal decompression maneuver for prolonged ischemic priapism when medical treatment has failed and the surgeon wants to clear the corporal compartment directly before committing the patient to immediate prosthesis insertion.

Evidence anchorFindings
Fuchs 2018Initial PSD series: 6/6 achieved detumescence and immediate pain relief; acute malleable prosthesis comparators had high revision / extrusion burden in ischemic tissue[18]
Baumgarten 2020Multi-institutional PSD series: detumescence achieved in all patients; bilateral PSD had 0% recurrence vs recurrence after unilateral decompression; 60% with follow-up reported spontaneous erections adequate for penetration[19]
Basile 2025Two-center proximal-shaft PSD series: 96% immediate detumescence, 92% complete pain relief, 69% overall success, and low complication rate; success was better with bilateral decompression and earlier intervention[20]
VanDyke 2023 surveyAmong high-volume male-genital surgeons who had performed both procedures, PSD was perceived as more effective than corporoglanular tunneling (47.3% vs 18.7% rating "very or extremely effective"), although tunneling remains more widely performed[21]

Practical algorithm for prolonged ischemic priapism:

  1. <24 h: aspiration / irrigation + phenylephrine; distal shunt if medical therapy fails.
  2. 24–36 h: distal shunt with tunneling or PSD, depending on surgeon experience and corporal clot burden.
  3. 36–48 h: PSD is a reasonable glans-sparing decompression option, especially if the patient wants any chance of native erectile recovery and understands the high ED risk.
  4. >48 h, MRI / exam suggesting nonviable corpora, or failed PSD: favor acute malleable penile prosthesis or planned delayed prosthesis strategy.

PSD vs acute prosthesis​

PSD avoids implanting hardware into swollen, ischemic, contaminated-by-clot tissue and keeps later inflatable penile prosthesis placement available under more controlled conditions. That is its major appeal. Its limitation is equally important: decompression may relieve pain and rigidity without restoring erectile function if smooth-muscle necrosis has already occurred.

Early penile prosthesis remains appropriate when the presentation is very late, corporal viability is doubtful, the patient prioritizes length preservation over native erectile recovery, or PSD / shunting fails. The EAU systematic review found prosthesis reliably resolves priapism but carries nontrivial complication risk, while post-shunting reviews emphasize that evidence after failed shunting remains retrospective and center-dependent.[22][23]

For priapism >36–48 hours, acute prosthesis implantation is on the menu of first-line options. The logic is simple: the corpus cavernosum will fibrose regardless of what shunt is performed; implanting a malleable device during the acute phase preserves length and avoids a far more technically demanding implant 4–6 weeks later through densely fibrotic corpora.[15]

Videos​

Priapism — technique demonstration
Ischemic priapism management
Priapism management — operative video
Surgical approach and shunt technique

External video references:

  • Penoscrotal decompression of refractory ischemic priapism — surgical technique — Videos in Sexual Medicine (vjsm.info): Residents Corner
  • Penoscrotal decompression — a better method for priapism management — Videos in Sexual Medicine (vjsm.info): Full video

See Also​

References​

1. Pang KH, Alnajjar HM, Lal A, Muneer A. An update on mechanisms and treatment options for priapism. Nat Rev Urol. 2025. doi:10.1038/s41585-025-01069-9

2. Bivalacqua TJ, Allen BK, Brock G, et al. Acute ischemic priapism: an AUA/SMSNA guideline. J Urol. 2021;206(5):1114–1121. doi:10.1097/JU.0000000000002236

3. Bivalacqua TJ, Allen BK, Brock GB, et al. The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: an AUA/SMSNA guideline. J Urol. 2022;208(1):43–52. doi:10.1097/JU.0000000000002767

4. Ericson C, Baird B, Broderick GA. Management of priapism: 2021 update. Urol Clin North Am. 2021;48(4):565–576. doi:10.1016/j.ucl.2021.07.003

5. Idris IM, Burnett AL, DeBaun MR. Epidemiology and treatment of priapism in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2022;2022(1):450–458. doi:10.1182/hematology.2022000380

6. Wen J, Jiang X, Dai Y, et al. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. FASEB J. 2010;24(3):740–9. doi:10.1096/fj.09-144147

7. Pereira DA, Calmasini FB, Costa FF, Burnett AL, Silva FH. Nitric oxide resistance in priapism associated with sickle cell disease: mechanisms, therapeutic challenges, and future directions. J Pharmacol Exp Ther. 2024;390(2):203–212. doi:10.1124/jpet.123.001962

8. Iacopucci APM, da Silva Pereira P, Pereira DA, et al. Intravascular hemolysis leads to exaggerated corpus cavernosum relaxation: implication for priapism in sickle cell disease. FASEB J. 2022;36(10):e22535. doi:10.1096/fj.202200867R

9. Chinegwundoh FI, Smith S, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev. 2020;4:CD004198. doi:10.1002/14651858.CD004198.pub4

10. Borrell JA, Bettencourt A, Furtado TP, et al. Risk factors, diagnosis, and long-term erectile dysfunction outcomes in priapism: a retrospective analysis of 186 cases from a single institution. Int J Impot Res. 2026;38(1):23–29. doi:10.1038/s41443-025-01076-9

11. von Stempel C, Walkden M, Kirkham A. Review of the role of imaging in the diagnosis of priapism. Int J Impot Res. 2024. doi:10.1038/s41443-024-00928-0

12. McHugh K, Gibbons RC. Point-of-care ultrasound diagnosis of high flow priapism. J Emerg Med. 2022;62(2):207–209. doi:10.1016/j.jemermed.2021.07.037

13. Graham BA, Abdulla W, Jack C, Mitchell RA, Hellstrom WJG. An overview of emergency pharmacotherapy for priapism. Expert Opin Pharmacother. 2022;23(12):1371–1380. doi:10.1080/14656566.2022.2099271

14. Lumbiganon S, Moukhtar Hammad MA, Azad B, Yafi FA. A narrative review of initial treatment for ischemic priapism. Int J Impot Res. 2024. doi:10.1038/s41443-024-00951-1

15. Yassin M, Chen R, Ager M, Desouky E, Minhas S. Penile implants in low flow priapism. Int J Impot Res. 2023;35(7):651–663. doi:10.1038/s41443-023-00787-1

16. El-Bahnasawy MS, Dawood A, Farouk A. Low-flow priapism: risk factors for erectile dysfunction. BJU Int. 2002;89(3):285–90. doi:10.1046/j.1464-4096.2001.01510.x

17. Masterson TA, Parmar M, Tradewell MB, et al. Using artificial intelligence to predict surgical shunts in men with ischemic priapism. J Urol. 2020;204(5):1033–1038. doi:10.1097/JU.0000000000001183

18. Fuchs JS, Shakir N, McKibben MJ, et al. Penoscrotal decompression-promising new treatment paradigm for refractory ischemic priapism. J Sex Med. 2018;15(5):797–802. doi:10.1016/j.jsxm.2018.02.010

19. Baumgarten AS, VanDyke ME, Yi YA, et al. Favourable multi-institutional experience with penoscrotal decompression for prolonged ischaemic priapism. BJU Int. 2020;126(4):441–446. doi:10.1111/bju.15127

20. Basile G, Ralph D, Wardak S, Sangster P, Christopher N, Lee WG. Penoscrotal decompression should be considered for prolonged ischaemic priapism. J Sex Med. 2025;22(11):2072–2078. doi:10.1093/jsxmed/qdaf229

21. VanDyke ME, Smith WJ, Holland LC, et al. Current opinions on the management of prolonged ischemic priapism: does penoscrotal decompression outperform corporoglanular tunneling? Int J Impot Res. 2024;36(1):62–67. doi:10.1038/s41443-023-00808-z

22. Milenkovic U, Cocci A, Veeratterapillay R, et al. Surgical and minimally invasive treatment of ischaemic and non-ischaemic priapism: a systematic review by the EAU Sexual and Reproductive Health Guidelines Panel. Int J Impot Res. 2024;36(1):36–49. doi:10.1038/s41443-022-00604-1

23. Schifano N, Capogrosso P, Baldini S, et al. Current evidence on the management of ischaemic priapism post-shunting: a narrative review. Int J Impot Res. 2025. doi:10.1038/s41443-025-01078-7